Skip to main navigation

Patients
Providers
- Patient Care
- Resources
Products
- Myriad Products
About
Contact

Generic selectors

Exact matches only

Exact matches only

Search in title

Search in title

Search in content

Search in content

Search in excerpt

Search in posts

Search in posts

Search in pages

Search in pages

Patients
Providers
- Patient Care
- Resources
Products
- Myriad Products
About
Contact

Investor Information

Investor Relations

Understanding Myriad
News Releases
Events & Presentations
- All
- 2021 Investor Day
Financial Reporting
Stock Information

Investor FAQs

More FAQs are coming soon.

Introducing riskScore™: A groundbreaking breast cancer risk-prediction tool

Stock Quote

Stock Quote



Intraday High:
52 Week High:
Intraday Low:
52 Week Low:
Volume

Data Provided by Refinitiv. Minimum 15 minutes delayed.

hcq-callout-bg.fw

Personalizing Prostate Cancer Treatment

Prolaris measures cancer aggressiveness to help personalize treatment for men with prostate cancer.

RSS

Payers
Overview

Investors
Events + Presentations

News
Press Releases
Myriad Genetics Blog

Careers
Joining the Team

Terms of Use
Myriad Genetics, Inc. Privacy Policy
Language Assistance

Cookie Preferences

© 2022 Myriad Genetics, Inc.

Website Feedback

Did you find what you were looking for?

YesNo

On a scale from 1-10, how visually appealing was the content?

1 - Very Bad 10 - Very Good

12345678910

On a scale from 1-10, based on your experience today, how likely are you to recommend Myriad.com to a friend or colleague?

1 - Not at all likely 10 - Extremely likely

12345678910

Please share any additional feedback that could help us improve our site experience.

If you would like to be contacted about your experience today, please provide your email address or reach out to the proper division

reCAPTCHA helps prevent automated form spam.

The submit button will be disabled until you complete the CAPTCHA.

Contact Information